Glucocorticoid excess and hypertension (original) (raw)

• Arnoldi G, Angeli A, Atkinson AB, et al.: Diagnosis and complications of Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593–5602.
  Article CAS Google Scholar
• Ross EJ, Linch DC: Cushing’s syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982, 2:646–649.
  Article PubMed CAS Google Scholar
• Stewart PM, Walker BR, Holder F: 11 beta-hydroxysteroid dehydrogense activity in Cushing’s syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metab 1995, 80:3617–3620.
  Article PubMed CAS Google Scholar
• Magiakou MA, Mastorakos G, Zachman K, et al.: Blood pressure in children and adolescents with Cushing’s syndrome before and after surgical cure. J Clin Endocrinol Metab 1997, 82:1734–1738.
  Article PubMed CAS Google Scholar
• Fraser R, Davies DL, Connell JMC: Hormones and hypertension. Clin Endocrinol 1989, 31:701–746. Changes in hormone secretion in human hypertension are reviewed, key papers are summarized, and controversial theories in the pathogenesis of glucocorticoid-induced hypertension and other forms of hormonal hypertension are discussed.
  CAS Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252. This report provides an evidence-based approach to the prevention and management of hypertension.
  Article PubMed CAS Google Scholar
• Extabe J, Vazquez JA: Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol (Oxf) 1994, 40:479–484.
  Google Scholar
• Torpy DJ, Mullen N, Ilias I, et al.: Association of hypertension and hypokalemia with Cushing’s syndrome caused by ectopic ACTH secretion. Ann N Y Acad Sci 2002, 970:134–144. This retrospective case review of 58 patients with ectopic ACTH secretion identifies common causes of this condition and reviews the incidence and prevalence of hypertension and hypokalemia in these patients.
  PubMed CAS Google Scholar
• Faggiano A, Pivonello R, Spiezia S, et al.: Cardiovascular risk factors and common carotid artery caliber and stiffness inpatients with Cushing’s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003, 88:2527–2533.
  Article PubMed CAS Google Scholar
• Panarelli M, Terzolo M, Piovesan A, et al.: 24-hour profiles of blood pressure and heart rate in Cushing’s syndrome: evidence for differential control of cardiovascular variables by glucocorticoids. Ann Ital Med Int 1990, 5:18–25.
  PubMed CAS Google Scholar
• Zelinka T, Strauch B, Pecen L, et al.: Diurnal blood pressure variation in pheochromocytoma, primary aldosteronism and Cushing’s syndrome. J Hum Hypertens 2004, 18:107–111.
  Article PubMed CAS Google Scholar
• Hatakeyama H, Inaba S, Miyamori I: 11beta-hydroxysteroid dehydrogenase in cultured human vascular cells: possible role in the development of hypertension. Hypertension 1999, 33:1179–1184.
  PubMed CAS Google Scholar
• Brem A, Bina R, King T, et al.: Localization of 2 11 beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31:459–462.
  PubMed CAS Google Scholar
• Ritchie CM, Sheridan B, Fraser R, et al.: Studies on the pathogenesis of hypertension in Cushing’s disease and acromegaly. Q J Med 1990, 280:855–867.
  Google Scholar
• Ulick S, Wang JZ, Blumenfeld JD, et al.: Cortisol inactivation overload: a mechanism of mineralocorticoid hypertension in the ectopic adrenocorticotropin syndrome. J Clin Endocrinol Metabol 1992, 74:963–967.
  Article CAS Google Scholar
• Quinkler M, Stewart PM: Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003, 88:2384–2392. The role of the cortisol-cortisone shuttle in human hypertension is reviewed. Specifically, SAME, ectopic ACTH production, and polymorphic variability in the HSD11B2 gene are discussed.
  Article PubMed CAS Google Scholar
• Dotsch J, Dorr HG, Stall GK, et al.: Effect of glucocorticoid excess on the cortisol/cortisone ratio. Steroids 2001, 66:817–820.
  Article PubMed CAS Google Scholar
• Ferrari P, Krozowski Z: Role of the 11beta-hydroxysteroid dehydrogenase type 2 in blood pressure regulation. Kidney Int 2000, 57:1374–1381.
  Article PubMed CAS Google Scholar
• Farman N, Bocchi B: Mineralocorticoid selectivity: molecular and cellular aspects. Kidney Int 2000, 57:1364–1369.
  Article PubMed CAS Google Scholar
• Connell JM, Whitworth JA, Davies DL, et al.: Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987, 5:425–433.
  Article PubMed CAS Google Scholar
• Mangos GJ, Whitworth JA, Williamson PM: Glucocorticoids and the kidney. Nephrology 2003, 8:267–273. The effect of glucocorticoids on renal metabolism, hemodynamics, and the role of the kidney in glucocorticoid hypertension are discussed.
  Article PubMed CAS Google Scholar
• Whitworth JA, Gordon D, Andrews J, et al.: The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537–549.
  Article PubMed CAS Google Scholar
• Nieman LK, Chrousos GP, Kellner C, et al.: Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985, 61:536–540.
  PubMed CAS Google Scholar
• Sala C, Ambrosi B, Morganti A: Blunted vascular and renal effects of exogenous atrial natriuretic peptide in patients with Cushing’s disease. J Clin Endocrinol Metab 2001, 86:1957–1961.
  Article PubMed CAS Google Scholar
• Yasunari K, Kohno M, Murakawa K, et al.: Glucocorticoids and atrial natriuretic factor receptors on vascular smooth muscle. Hypertension 1990, 16:581–586.
  PubMed CAS Google Scholar
• Kelm M: The L-arginine-nitric oxide pathway in hypertension. Curr Hypertens Rep 2003, 5:80–86.
  Article PubMed Google Scholar
• Axelrod L: Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing’s syndrome and Addison’s disease. Lancet 1983, 23:904–906.
  Article Google Scholar
• Saruta T, Suzuki H, Handa M, et al.: Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrinol Metab 1986, 62:275–279.
  PubMed CAS Google Scholar
• Scheuer DA, Becht AG: Glucocorticoids potentiate central actions of angiotensin to increase arterial pressure. Am J Physiol Regul Integr Comp Physiol 2001, 280:R1719-R1726.
  PubMed CAS Google Scholar
• Pirpiris, M, Sudhir K, Yeung S, et al.: Pressor responsiveness in corticosteroid-induced hypertension in humans. J Hypertens 1989, 7:537–549.
  Article Google Scholar
• McKnight JA, Rooney DP, Whitehead H, et al.: Blood pressure responses to phenylephrine infusions in subjects with Cushing’s syndrome. J Hum Hypertens 1995, 9:855–858.
  PubMed CAS Google Scholar
• Sato A, Suzuki H, Murakami M, et al.: Glucocorticoid increases angiotensin II type 1 receptor and its gene expression. Hypertension 1994, 23:25–30.
  PubMed CAS Google Scholar
• Arai H, Hori S, Aramori I, et al.: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348:730–732.
  Article PubMed CAS Google Scholar
• Kirilov G, Tomova A, Dakovska L, et al.: Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing’s syndrome. Eur J Endocrinol 2003, 149:549–553.
  Article PubMed CAS Google Scholar
• Quaschning T, Ruschitzka F, Niggli B, et al.: Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 2001, 16:2146–2151.
  Article PubMed CAS Google Scholar
• Shelat, SG, King JL, Flanagan-Cato LM, et al.: Mineralocorticoids and glucocorticoids cooperatively increase salt intake and angiotensin II receptor binding in rat brain. Neuroendocrinology 1999, 69:339–351.
  Article PubMed CAS Google Scholar
• Van Uum SH, Houben AJ, Hermus AR, et al.: Acute intrarenal administration of cortisol has no effect on renal blood flow in hypertensive individuals. J Hypertens 2002, 20:2275–2283.
  Article PubMed Google Scholar
• Zimmerman BG, Dunham EW.: Tissue renin-angiotensin system: A site of drug action? Ann Rev Pharmacol Toxicol 1997, 37:53–69.
  Article CAS Google Scholar
• Nishiyama A, Fujisawa Y, Fukui T, et al.: Role of nitric oxide in regional blood flow in angiotensin II-induced hypertensive rats. Hypertens Res 2001, 24:421–427.
  Article PubMed CAS Google Scholar
• Souness GW, Brem AS, Morris DJ: 11 beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids 2002, 67:195–201.
  Article PubMed CAS Google Scholar
• Donmez G, Derici U, Erbas D, et al.: The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn J Physiol 2002, 52:435–440.
  Article PubMed CAS Google Scholar
• Tsikouris JP, Cox CD: Pharmacologic blockade of the reninangiotensin system: vascular benefits beyond commonly understood pharmacologic actions. Pharmacotherapy 2003, 23:1141–1152.
  Article PubMed CAS Google Scholar
• Di Girolamo G, Gonzalez E, Livio D, et al.: The effect of enalapril on PGI(2) and NO levels in hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 2002, 66:493–498.
  Article PubMed Google Scholar
• Yagi S, Morita T, Katayama S: Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004, 27:129–135.
  Article PubMed CAS Google Scholar
• Dalakos TG, Elias AN, Anderson GH Jr, et al.: Evidence for an angiotensinogenic mechanism of the hypertension of Cushing’s syndrome. J Clin Endocrinol Metab 1978, 46:114–118.
  PubMed CAS Google Scholar
• Zacharieva S, Orbetzova M, Natchev E, et al.: Losartan in Cushing’s syndrome. Methods Find Exp Clin Pharmacol 1998, 20:163–168.
  Article PubMed CAS Google Scholar
• Fallo F, Paoletta A, Tona F, et al.: Response of hypertension to conventional antihypertensive treatment and/or steroidogenesis inhibitors in Cushing’s syndrome. J Intern Med 1993, 234:595–598.
  Article PubMed CAS Google Scholar
• Fallo F, Sonino N, Barzon L, et al.: Effect of surgical treatment on hypertension in Cushing’s syndrome. Am J Hypertens 1996, 9:77–80.
  Article PubMed CAS Google Scholar
• Colao A, Pivonello R, Spiezia S, et al.: Persistence of increased cardiovascular risk in patients with Cushing’s disease after five years of successful cure. J Clin Endocrinol Metab 1999, 84:2664–2672.
  Article PubMed CAS Google Scholar
• Seckl JR, Morton NM, Chapman KE, et al.: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004, 59:359–393.
  Article PubMed CAS Google Scholar
• Andrew R, Phillips DIW, Walker BR: Obesity and gender influence cortisol secretion and metabolism in man. J Clin Endocrinol Metab 1998, 83:1806–1809.
  Article PubMed CAS Google Scholar
• Fraser R, Ingram MC, Anderson NH, et al.: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33:1364–1368.
  PubMed CAS Google Scholar
• Stewart PM, Boulton A, Kumar S, et al.: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999, 84:1022–1027.
  Article PubMed CAS Google Scholar